DE60018744D1 - Komplex von Eletriptan und Sulfobutylether-cyclodextrin und dessen Verwendung zur Behandlung von Migräne - Google Patents

Komplex von Eletriptan und Sulfobutylether-cyclodextrin und dessen Verwendung zur Behandlung von Migräne

Info

Publication number
DE60018744D1
DE60018744D1 DE60018744T DE60018744T DE60018744D1 DE 60018744 D1 DE60018744 D1 DE 60018744D1 DE 60018744 T DE60018744 T DE 60018744T DE 60018744 T DE60018744 T DE 60018744T DE 60018744 D1 DE60018744 D1 DE 60018744D1
Authority
DE
Germany
Prior art keywords
eletriptan
migraine
complex
treatment
sulfobutyl ether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60018744T
Other languages
English (en)
Other versions
DE60018744T2 (de
Inventor
Anne Billotte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of DE60018744D1 publication Critical patent/DE60018744D1/de
Publication of DE60018744T2 publication Critical patent/DE60018744T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60018744T 1999-06-29 2000-06-02 Komplex von Eletriptan und Sulfobutylether-cyclodextrin und dessen Verwendung zur Behandlung von Migräne Expired - Lifetime DE60018744T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9915231.6A GB9915231D0 (en) 1999-06-29 1999-06-29 Pharmaceutical complex
GB9915231 1999-06-29
PCT/IB2000/000746 WO2001000243A1 (en) 1999-06-29 2000-06-02 Pharmaceutical complex

Publications (2)

Publication Number Publication Date
DE60018744D1 true DE60018744D1 (de) 2005-04-21
DE60018744T2 DE60018744T2 (de) 2006-05-18

Family

ID=10856302

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60018744T Expired - Lifetime DE60018744T2 (de) 1999-06-29 2000-06-02 Komplex von Eletriptan und Sulfobutylether-cyclodextrin und dessen Verwendung zur Behandlung von Migräne

Country Status (44)

Country Link
US (2) US6713461B1 (de)
EP (1) EP1189640B1 (de)
JP (2) JP4454900B2 (de)
KR (1) KR20020015067A (de)
CN (1) CN1198654C (de)
AP (1) AP2001002369A0 (de)
AR (1) AR033337A1 (de)
AT (1) ATE290884T1 (de)
AU (1) AU770169B2 (de)
BG (1) BG106151A (de)
BR (1) BR0011845A (de)
CA (1) CA2376847C (de)
CO (1) CO5170494A1 (de)
CZ (1) CZ20014572A3 (de)
DE (1) DE60018744T2 (de)
DZ (1) DZ3320A1 (de)
EA (1) EA003908B1 (de)
EC (1) ECSP003551A (de)
EE (1) EE200100697A (de)
ES (1) ES2235879T3 (de)
GB (1) GB9915231D0 (de)
GE (1) GEP20043377B (de)
GT (1) GT200000102A (de)
HR (1) HRP20010951A2 (de)
HU (1) HUP0201629A3 (de)
IL (1) IL146341A0 (de)
IS (1) IS6163A (de)
MA (1) MA26801A1 (de)
MX (1) MXPA01013274A (de)
NO (1) NO20016430L (de)
NZ (1) NZ515235A (de)
OA (1) OA11964A (de)
PA (1) PA8496801A1 (de)
PE (1) PE20010346A1 (de)
PL (1) PL352902A1 (de)
SK (1) SK18932001A3 (de)
SV (1) SV2002000112A (de)
TN (1) TNSN00142A1 (de)
TR (1) TR200103827T2 (de)
UA (1) UA66932C2 (de)
UY (1) UY26224A1 (de)
WO (1) WO2001000243A1 (de)
YU (1) YU87501A (de)
ZA (1) ZA200110454B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
SI1542668T1 (sl) 2002-08-20 2009-08-31 Bristol Myers Squibb Co Aripiprazol sestavljena formulacija in postopek
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
CN1296391C (zh) * 2004-03-04 2007-01-24 中国人民解放军第二军医大学 氟代羧烷基环糊精醚类化合物及其制备方法和应用
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
CN101957330B (zh) * 2010-06-12 2013-10-09 南京巨环医药科技开发有限公司 磺丁基倍他环糊精含量的测定方法
WO2017122161A1 (en) * 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
US20190224171A1 (en) * 2018-01-22 2019-07-25 Insys Development Company, Inc. Liquid rizatriptan compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
HU211648A9 (en) 1990-03-28 1995-12-28 Chinoin Gyogyszer Es Vegyeszet Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same
HU210921B (en) 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
RU2095360C1 (ru) 1990-10-15 1997-11-10 Пфайзер Инк. Производные индола, их оптические изомеры и фармацевтически приемлемые соли
RU2143896C1 (ru) 1993-03-05 2000-01-10 Хексаль Аг Кристаллический комплекс циклодекстрина с гидрохлоридом ранитидина, способ его получения и содержащие его фармацевтические составы
JPH08510761A (ja) 1994-03-07 1996-11-12 ザ・ダウ・ケミカル・カンパニー 生物活性及び／又はターゲテッドデンドリマー複合体
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
WO1998002186A1 (en) 1996-07-11 1998-01-22 Farmarc Nederland B.V. Inclusion complex containing indole selective serotonin agonist
US5998462A (en) 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
PL337803A1 (en) 1997-07-03 2000-09-11 Pfizer Pharmaceutic agents containing eletriptane hemisulphate and caffeine
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex

Also Published As

Publication number Publication date
EP1189640B1 (de) 2005-03-16
EA003908B1 (ru) 2003-10-30
NZ515235A (en) 2003-08-29
WO2001000243A1 (en) 2001-01-04
BR0011845A (pt) 2002-03-05
PA8496801A1 (es) 2002-02-21
IL146341A0 (en) 2002-07-25
UY26224A1 (es) 2001-01-31
SK18932001A3 (sk) 2002-09-10
CZ20014572A3 (cs) 2002-08-14
AP2001002369A0 (en) 2001-12-31
IS6163A (is) 2001-11-16
CA2376847C (en) 2007-09-25
TR200103827T2 (tr) 2002-05-21
CO5170494A1 (es) 2002-06-27
MXPA01013274A (es) 2002-06-04
CN1359303A (zh) 2002-07-17
JP2003503364A (ja) 2003-01-28
UA66932C2 (en) 2004-06-15
US20040186076A1 (en) 2004-09-23
EA200101106A1 (ru) 2002-06-27
AU4774100A (en) 2001-01-31
CN1198654C (zh) 2005-04-27
AU770169B2 (en) 2004-02-12
HRP20010951A2 (en) 2005-04-30
SV2002000112A (es) 2002-02-05
PE20010346A1 (es) 2001-03-26
ATE290884T1 (de) 2005-04-15
GEP20043377B (en) 2004-04-13
TNSN00142A1 (fr) 2005-11-10
DZ3320A1 (fr) 2001-01-04
PL352902A1 (en) 2003-09-22
ECSP003551A (es) 2002-01-25
DE60018744T2 (de) 2006-05-18
YU87501A (sh) 2004-05-12
EE200100697A (et) 2003-02-17
GT200000102A (es) 2001-12-14
JP2006257091A (ja) 2006-09-28
AR033337A1 (es) 2003-12-17
BG106151A (en) 2002-05-31
JP4454900B2 (ja) 2010-04-21
EP1189640A1 (de) 2002-03-27
ES2235879T3 (es) 2005-07-16
HUP0201629A3 (en) 2003-11-28
US6713461B1 (en) 2004-03-30
OA11964A (en) 2006-04-17
MA26801A1 (fr) 2004-12-20
NO20016430D0 (no) 2001-12-28
NO20016430L (no) 2002-02-26
HUP0201629A2 (hu) 2003-03-28
KR20020015067A (ko) 2002-02-27
GB9915231D0 (en) 1999-09-01
CA2376847A1 (en) 2001-01-04
ZA200110454B (en) 2002-12-20

Similar Documents

Publication Publication Date Title
DE60022917D1 (de) Reboxetin zur Behandlung von Migränekopfschmerzen
DE60033030D1 (de) Verwendung von gegen cd20 gerichteten antikörpern zur behandlung der graft versus host krankheit
ATE269303T1 (de) Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE255888T1 (de) Tetrahydronaphtalene verbindungen und deren verwendung zur behandlung von neurodegenerativen krankheiten
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
ATE251903T1 (de) Verwendung von phosphororganischen verbindungen zur therapeutischen und prophylaktischen behandlung von infektionen
ATE400283T1 (de) Reovirus zur behandlung von zellulären proliferativen erkrankungen
DE69934112D1 (de) Implantierbarer gewebeverschluss und system zur behandlung gastroösophagischen rückflusses
ATE350364T1 (de) Adamantanderivate zur behandlung von entzündlichen, immunologischen und kardiovaskulären erkrankungen
ATE276245T1 (de) Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
DE69738045D1 (de) Verwendung von cetrorelix zur behandlung von benigne prostatahypertrophie und prostatakrebs
ATE295174T1 (de) Arzneimittel zur behandlung von bluthochdruck
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE60018744D1 (de) Komplex von Eletriptan und Sulfobutylether-cyclodextrin und dessen Verwendung zur Behandlung von Migräne
DE60038458D1 (de) Verwendung von polymerem material zur behandlung harter oberflächen
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE69914951D1 (de) Substituierte tricyclische Verbindungen und deren Verwendung zur Behandlung von sPLA2-bedingten Erkrankungen
DE50111926D1 (de) Strahlungsanordnung sowie deren Verwendung und Verfahren zur Behandlung von Oberflächen
DE60001725D1 (de) Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
ATE299371T1 (de) Antikonvulsiva zur behandlung von autismus
DE60018200D1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE60003550D1 (de) Substituierte 3-pyridyl-4-arylpyrrole und deren einsatz in verfahren zur therapeutischen und prophylaktischen behandlung
DE60141979D1 (de) Verwendung von endothelin antagonisten zur behandlung von knochenkrebs und damit verbundenen schmerzen
ATE300531T1 (de) Isonipecotamide zur behandlung von integrin vermittelten störungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition